Next generation revolutionary
biopharmaceutical platform company
AbFinder Therapeutics Co., Ltd. is a R&D company of biopharmaceutics based on innovative platform technologies including "PepFc® platform“, which is the one and only small peptide platform technology replacing Fc of IgG, and "AbFinder® platform“, which is a platform technology carrying out from discovering antibody therapeutics to engineering.

PepFc ® A short peptide that has only the pH-dependent FcRn binding ability of Fc developed with our proprietary technology / AbFinder ® Efficient antibody discovery and engineering platform technology created by our own optimized antibody library (Material resource) and diverse antibody discovery and engineering experience (Human resource).